Safety, Immunogenicity, and Protection Provided by Unadjuvanted and Adjuvanted Formulations of a Recombinant Plant-Derived Virus-Like Particle Vaccine Candidate for COVID-19 in Nonhuman Primates

Investigators reported the immunogenicity and protection induced in rhesus macaques by intramuscular injections of a virus-like particle bearing a SARS-CoV-2 spike protein vaccine candidate formulated with or without Adjuvant System 03 or cytidine-phospho-guanosine 1018.